GlassScriptPhysician profile
Mariah L Schurman
NPI 1003413683
$1,482.61
in general payments reported to CMS, 2019-2025
20 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $172 · 2023: $269 · 2024: $377 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $222.78 | 2023-2024 | Vasoview Hemopro 2 |
| Abiomed | $207.64 | 2023-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $199.30 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.55 | 2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $95.91 | 2021-2022 | |
| Atricure, INC. | $91.77 | 2021-2025 | Atriclip Laa Exclusion System |
| Amgen INC. | $91.65 | 2021-2025 | Repatha, Repatha |
| La Jolla Pharmaceutical Company | $74.25 | 2022-2025 | Giapreza |
| Actelion Pharmaceuticals US, INC. | $74.16 | 2021-2023 | Uptravi, Opsumit |
| Haemonetics Corporation | $64.86 | 2024 | Teg6s Hemostasis System |
| Becton, Dickinson and Company | $33.96 | 2024 | Progel Applicator Spray Tips |
| Smith+Nephew, INC. | $33.70 | 2024 | Stravix |
| Ethicon US, LLC | $32.22 | 2023-2024 | Ethicon, Stratafix, Evarrest |
| Kiniksa Pharmaceuticals International, Plc | $26.79 | 2024 | Arcalyst |
| Davol INC. | $26.37 | 2025 | Progel Applicator Spray Tips |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.52 | 2022 | |
| Scpharmaceuticals INC. | $20.32 | 2024 | |
| Daiichi Sankyo INC. | $20.31 | 2023 | Injectafer |
| Chiesi USA, INC. | $15.87 | 2021 | |
| Amarin Pharma, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Schurman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.